Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Evkeeza (evinacumab-dgnb) is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• LDL-C Reduction: Evinacumab led to a significant reduction in LDL-C levels, with a mean difference of -33.123% (95% CI, -48.639% to -17.606%, P < 0.0001) compared to placebo.
• Triglycerides Reduction: Evinacumab significantly decreased triglyceride levels by -50.959% (95% CI, -56.555% to -45.362%, P < 0.0001).
• HDL-C Reduction: Evinacumab also resulted in a reduction of HDL-C levels, with a mean difference of -12.773% (95% CI, -16.359% to -9.186%, P < 0.0001).
• The incidence of at least one treatment-emergent adverse event was not significantly different between the evinacumab and placebo groups (relative risk 1.080, 95% CI, 0.901-1.296, P = 0.405).
• No significant safety concerns or specific adverse effects were highlighted for any particular population or subgroup, including those with familial hypercholesterolemia (FH).